Use of T cell-associated proteins in cancer treatment

JP2026519471APending Publication Date: 2026-06-16BOEHRINGER INGELHEIM INT GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
BOEHRINGER INGELHEIM INT GMBH
Filing Date
2024-05-17
Publication Date
2026-06-16

AI Technical Summary

Benefits of technology

【0146】 好ましい増加用量は、約80~100μg/kg、例えば約90μg/kgである。それに関連して、約90μg/kgが治療の観点で最小の有効用量と考えられることに注目すると、治療の観点における有益な効果が前記増加用量に応答して既に生じ得ることが注目される。

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2026519471000028
    Figure 2026519471000028
  • Figure 2026519471000029
    Figure 2026519471000029
  • Figure 2026519471000030
    Figure 2026519471000030
Patent Text Reader

Abstract

The present invention generally relates to the treatment of cancer by using DLL3 / CD3 binding proteins, and more particularly to the use and methods of using DLL3 / CD3 binding proteins in dose and administration regimens for the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art